Tagged with IPSE

Japan Eric Delarge, general manager and representative director of Servier Japan, recently became the first member of the international pharma industry to join bioIPSeeds, an innovative tool aiming to foster early stage collaboration between academia and the global industry, which also stands as the first application of the blockchain technology in…

Taiwan Carol Cheng, COO of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), the association gathering 28 Taiwan-based, R&D-driven biopharmaceutical companies, highlights the association’s eye-catching initiative to boost international collaboration between academia and the global industry, thanks to the recent set up of the BioIPSeeds® platform, which proudly stands as the first…

Ipsen These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global…

Manufacturing James Byrne, VP Site for Ipsen Manufacturing Ireland, discusses the strategic importance of the Ireland site as the sole provider of peptides for products generating over 50 percent of Ipsen’s global revenues; his strategy for attracting and retaining the best talent; and his thoughts on the impact of new manufacturing…

France Marc de Garidel reveals how 2015 has been Ipsen’s best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake France to become their number one affiliate. Mr de Garidel also explains Ipsen’s key growth drivers for the next five…

Ipsen Mexico is a key market for Ipsen to consolidate its footprint in the Americas. The recently appointed general manager and the medical director of the Mexican affiliate discuss how penetrating the market is a hard, yet not impossible mission, how Mexican patients are increasingly involved in Ipsen’s global clinical trials…

Ipsen Czech Republic Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you find are the greatest differences between the Czech pharma industry you joined in 1993 with Wellcome, and the industry you…

Ipsen Brazil In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of the newer international companies to Brazil, and you have been here since ground zero in 2007. What prompted that initial…

Ipsen Farmaceutica BV Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen, what has been the professional trajectory that has brought you to the head of this local affiliate? I came here…

Ipsen Poland When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone performed in the same period? It is my personal privilege and pride to say that 2010 was an extremely good…

Beaufour IPSEN China Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you to the pharmaceutical industry? I have a very long personal history with China, starting back in my student days. I…

Ipsen Ukraine Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian operations of Ipsen been faring in comparison to the global performance of the company? Let me first provide you a…